Form 4: Kiniksa Pharmaceuticals Executive Eben Tessari Reports Stock Transactions
SEC Form 4 Filing
Eben Tessari, Chief Operating Officer of Kiniksa Pharmaceuticals, reports the vesting of restricted share units and subsequent tax withholding.
Summary
- Eben Tessari, the Chief Operating Officer of Kiniksa Pharmaceuticals, reported transactions involving Class A Common Shares on April 1, 2024.
- These transactions included the vesting of 1,773 Restricted Share Units (RSUs) and the withholding of 521 shares to cover tax obligations.
- Following these transactions, Tessari directly owns 124,099 Class A Common Shares and 5,318 Restricted Share Units.
Sentiment
Score: 5
Explanation: This is a neutral report of stock transactions by a company executive, with no inherent positive or negative implications for the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their stock transactions. It allows investors to monitor the actions of company executives and their potential impact on the stock's performance.
Stakeholder Impact
- The transactions have a minimal impact on shareholders, as they represent a small portion of the total outstanding shares.
- The vesting of RSUs is part of the executive's compensation package, aligning their interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| April 1, 2023 | Grant date of the Restricted Share Units (RSUs) that vest over a four-year period. |
| April 1, 2024 | Date of the reported transactions: vesting of RSUs and tax withholding. |
| April 3, 2024 | Date of the signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.